| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC0285 |
| Trial ID | NCT02650986 |
| Disease | Fallopian Tube Cancer | Melanoma | Ovarian Carcinoma | Synovial Sarcoma | Peritoneal Carcinoma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| HLA | HLA-A*02:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase I/IIa Study of TGFβ Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies |
| Year | 2015 |
| Country | United States |
| Company sponsor | Roswell Park Cancer Institute |
| Other ID(s) | I 258514|NCI-2015-02080|I 258514|P30CA016056|R01CA164333 |
| Cohort1: dose level 1 | |||||||||||||||
|
|||||||||||||||
| Cohort2: dose level 2 | |||||||||||||||
|
|||||||||||||||